Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Rhea-AI Summary

Intensity Therapeutics (Nasdaq: INTS) was granted a 180-calendar-day extension by Nasdaq to regain compliance with the exchange's $1.00 minimum bid price requirement under Listing Rule 5550(a)(2).

The initial 180-day period expired on December 3, 2025; the new compliance deadline is June 1, 2026. To regain compliance the company must maintain a closing bid of at least $1.00 per share for ten consecutive business days on or before June 1, 2026. The notification does not affect listing or trading, and shares will continue to trade on the Nasdaq Capital Market under the symbol INTS. The company said it will monitor the closing bid and take actions as needed to cure the deficiency before the end of the extension period.

Positive

• Nasdaq granted a 180-day extension until June 1, 2026
• Common shares will continue trading on Nasdaq under INTS

Negative

• Must achieve a $1.00 closing bid for 10 consecutive business days by June 1, 2026
• Initial compliance period expired on December 3, 2025

Key Figures

Extension length 180 calendar days Additional period granted by Nasdaq to regain bid price compliance

Minimum bid requirement $1.00 per share Nasdaq Listing Rule 5550(a)(2) minimum closing bid price

Compliance window end June 1, 2026 Deadline to satisfy Nasdaq Minimum Bid Price Requirement

Required streak 10 consecutive business days Minimum period closing bid must be at or above $1.00

Current price $0.4629 Pre-news trading level vs. $1.00 Nasdaq requirement

52-week high $3.1663 INTS trades 85.38% below this level pre-announcement

52-week low $0.1853 INTS stands 149.81% above this level pre-announcement

Nasdaq rule Rule 5550(a)(2) Listing rule defining the minimum $1.00 bid price requirement

Market Reality Check

$0.4629 Last Close

Volume Volume 13,460,055 is 3.27x the 20-day average of 4,111,339, indicating elevated trading interest pre-announcement. high

Technical Shares at 0.4629 are trading below the 200-day MA of 0.74 and 85.38% under the 52-week high.

Peers on Argus 1 Up

INTS showed notable pre-news activity while sector peers were mixed: SNSE up 14.78%, ERNA up 8.62%, LYRA up 10.62%, MBRX up 1.46%, and BOLT down 0.96%, with only SNSE flagged in momentum scanners.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 06	Earnings update	Positive	-14.9%	Q3 2025 results and cash runway extension through end of Q1 2027.
Oct 31	Equity offering	Negative	-44.7%	Pricing of $4.0M registered direct common stock offering at $0.80.
Oct 30	Clinical data	Positive	+394.6%	Publication of INT230-6 Phase 1/2 data showing 75% disease control rate.
Sep 10	Trial update	Neutral	-9.6%	INVINCIBLE-4 update with first pCR but temporary enrollment pause for skin irritation.
Sep 02	Conference participation	Neutral	-2.5%	Planned fireside chat at H.C. Wainwright 27th Annual Global Investment Conference.

Pattern Detected

News tied to equity offerings has coincided with sharp declines, while strong clinical data has seen outsized gains. Operational or conference updates have often met with muted or negative reactions.

Recent Company History

Over the last six months, INTS has balanced financing needs with clinical progress. A positive eBioMedicine publication on INT230-6 on Oct 30, 2025 saw a 394.57% move, while a $4.0M registered direct offering on Oct 31, 2025 coincided with a -44.68% reaction. Q3 2025 results on Nov 6, 2025 extended cash runway but the stock fell 14.86%. Today’s Nasdaq bid-price extension fits into an ongoing effort to maintain listing amid prior reverse-split approvals and capital raises.

Market Pulse Summary

The stock is up +5.4% following this news. A strong positive reaction aligns with relief around maintaining Nasdaq listing as INTS works to cure its bid-price deficiency by June 1, 2026. The company already secured stockholder approval for a reverse split range and has relied on equity offerings to extend its runway to the end of Q1 2027. However, prior financings have coincided with sharp drops, so additional capital actions could temper sustainability.

Key Terms

intratumoral medical

"novel intratumoral cancer therapies that are designed to kill tumors"

"Intratumoral" describes something that occurs or exists within a tumor, which is an abnormal growth of tissue. For investors, understanding intratumoral is important because it relates to medical treatments or research aimed at targeting the tumor directly, potentially leading to more effective therapies. Think of it as focusing treatment straight into the problem area, much like fixing a leak by working directly on the pipe itself.

AI-generated analysis. Not financial advice.

SHELTON, Conn., Dec. 5, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that it has been granted a 180 calendar day extension from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on Nasdaq (the "Minimum Bid Price Requirement"), following the expiration of the initial 180 calendar day period to regain compliance on December 3, 2025, which was initially granted on June 6, 2025. The Company now has until June 1, 2026 to meet the Minimum Bid Price Requirement set forth in Nasdaq Listing Rule 5550(a)(2).

The notification has no immediate effect on the listing or trading of the Company's shares of common stock, which will continue to trade on the Nasdaq Capital Market under the symbol "INTS." To regain compliance with the Rule, the Company must maintain a closing bid price of at least $1.00 per share for a minimum of ten (10) consecutive business days on or prior to the 180-day extension period, or June 1, 2026. The Company intends to actively monitor the closing bid price of its common stock between now and the end of the extension period and intends to take all appropriate actions to cure the deficiency and regain compliance with the Rule prior to the end of the compliance period.

About Intensity Therapeutics

Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor's dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies and enrolled over 200 patients using INT230-6; a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the "INVINCIBLE-2 Study") (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the "INVINCIBLE-3 Study") (NCT06263231), testing INT230-6 as second or third line monotherapy compared to the standard of care ("SOC") with overall survival as an endpoint. Intensity also initiated a Phase 2 study (the "INVINCIBLE-4 Study") (NCT06358573) in collaboration with the Swiss Cancer Group, formerly the Swiss Group for Clinical Cancer Research SAKK, as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. Pathological complete response ("pCR") is the endpoint. For more information about Intensity, including publications, papers and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com.  

About INT230-6

INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform. The drug consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule ("SHAO") that facilitates the dispersion of potent cytotoxic drugs throughout tumors, allowing the active agents to diffuse into cancer cells. These agents remain in the tumor, resulting in a favorable safety profile. In addition to local disease control and direct tumor killing, INT230-6 causes a release of a bolus of neoantigens specific to the malignancy, leading to immune system engagement and systemic anti-tumor effects. Importantly, these effects are mediated without immunosuppression, which often occurs with systemic chemotherapy.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company's expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company's research to generate and advance additional product candidates; the risk that product candidates that appear promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials; the implementation of the Company's business model, strategic plans for the Company's business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company's system; the Company's competitive position; the Company's intellectual property position; developments and projections relating to the Company's competitors and its industry; the Company's ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; our potential inability to satisfy the Nasdaq Capital Market's requirements for continued listing and be subject to delisting; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other risks described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company's subsequent SEC filings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Investor Relations Contact:
Justin Kulik
justin@coreir.com
(516) 222-2560

Media Contact:
Matt Cossel
CORE IR
PR@coreir.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/intensity-therapeutics-granted-180-day-extension-to-regain-compliance-with-nasdaqs-minimum-bid-price-requirement-302633691.html

SOURCE Intensity Therapeutics Inc.

FAQ

What deadline did Nasdaq set for INTS to regain compliance with the $1.00 minimum bid price?

Nasdaq granted INTS until June 1, 2026 to meet the minimum bid price requirement.

How long must INTS maintain a closing bid above $1.00 to regain compliance?

INTS must maintain a closing bid of at least $1.00 for 10 consecutive business days on or before the June 1, 2026 deadline.

Does the Nasdaq notification affect trading of INTS shares?

No; the notification has no immediate effect on listing or trading and shares will continue to trade on Nasdaq under INTS.

When did the initial Nasdaq compliance period for INTS expire?

The initial 180-day compliance period expired on December 3, 2025.

What action did Intensity Therapeutics say it will take regarding the Nasdaq deficiency?

The company intends to actively monitor the closing bid and take all appropriate actions to cure the deficiency and regain compliance before the deadline.